Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized Bacteriophage Therapy
- Development stage
- Unknown
- Lead developer
- BiomX, Inc.
- Administration
- Intravenous, Intravesical
01
Overview
Adaptive Phage Therapeutics (APT) is developing a personalized bacteriophage therapy for the treatment of urinary tract infections (UTIs) caused by multidrug-resistant bacteria, specifically *Escherichia coli* and *Klebsiella pneumoniae*. This biologic therapy utilizes APT's PhageBank™, a continually expanding library of bacteriophages, to provide a tailored treatment approach. For each patient, a PhageBank Susceptibility Test™ (PST), developed in collaboration with Mayo Clinic Laboratories, is used to identify specific phages from the library that are active against the patient's unique bacterial isolate. These selected phages are then formulated into a personalized cocktail and administered either intravenously or via bladder instillation (intravesically). The therapy is designed to specifically infect and lyse the target uropathogenic bacteria while sparing the host's commensal microbiome. The program is supported by the U.S. Department of Defense and is currently being evaluated in a Phase 1/2 clinical trial.
- Other names
- Personalized Bacteriophage TherapyPhageBank therapyAPT-UTI
Beyond the preview
Go deeper on Personalized Bacteriophage Therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized Bacteriophage Therapy.